Analysis Of Prognosis In Patients With Advanced Lung Adenocarcinoma

Objective: The aim of this study is to filter the prognostic factors in200cases ofadvanced lung adenocarcinoma patients，and to predict the possibility of recurrence foradvanced lung adenocarcinoma patients, so that we can achieve reasonable treatment totreatment and improve the survival.Methods:The clinical data of200patients with advanced lung adenocarcinoma in FirstAffiliated Hospital of Dalian Medical University from January2006to February2011were retrospectively analyzed and follow-up，male:93cases, female:107cases.All thosepatients had accepted two kinds of theropy-chemotheropy and targeted theropy.UsingKaplan-Meier test for univariate analysis to clear clinical factors associated with1and2-year survival rate. Putting the significant differences into the COX model regressionmethod and identify the risk factors for the advanced lung adenocarcinoma.Stratified analysis:126cases choose the chemotherapy as first-line therapy while74cases choose the targeted-therapy as the first-line therapy.Group A(The first-linetherpy is chemotherapy and the second-line is Iressa):88cases;Group B(The first-linetherpy is Iressa and the second-line is chemotherapy):44cases. Analysis the OS of allthose patients, and compared groups A and group B with OS,1-year survival rate,2and3-year survival rate.Results:The median survival time of200patients is17months.1,2and3-year survivalrate was66.0%,27.5%and7.5%respectively in the whole group.The clinical factorswere analyzed by Kaplan-Meier analysis, results showed that: ECOG score,the brainmetastases,the number of metastases,percentage of weight loss and the first-linetherapy were related to1and2-year survival rate of advanced lung adenocarcinoma.COX model regression method analysis showed the risk factors ofadvanced lung adenocarcinoma were ECOG score,the brain metastases,the number ofmetastases and the percentage of weight loss.The first-line is chemotherapy group had18months median survival time;1,2and3-year survival rate was71.4%,32.5%and8.7%.The first-line is targeted-therapy group had15months median survival time;1,2and3-year survival rate was56.8%,18.9%and5.4%.Group A had24months mediansurvival time.1,2and3-year survival rate was80.7%,44.3%and10.2%.Group B had22months median survival time.1,2and3-year survival rate was88.6%,43.2%and6.8%,Median survival between the two groups was statistically significant difference inOS (P=0.025).Conclusions:1.The median survival time of200patients is17months.1,2and3-yearsurvival rate was66.0%,27.5%and7.5%respectively in the whole group.2.ECOG score,the brain metastases,the number of metastases,percentageof weight loss and the first-line therapy were related to1and2-year survival rate ofadvanced lung adenocarcinoma.ECOG score,the brain metastases,the number ofmetastases and the percentage of weight loss.The risk factors of recurrence of advancedlung adenocarcinoma were ECOG score,the brain metastases,the number of metastasesand percentage of weight loss.ECOG score0-1,no brain metastases,the number ofmetastases was less than2and tne weight loss was less than5%had tne longer MST.3.The first-line therpy is chemotherapy and the second-line is Iressa hasthe longer MST than the first-line therpy is Iressa and the second-line is chemotherapy.